We found that unlike vemurafenib, which is only effective in patients harboring BRAFV600E mutant melanomas, targeting MCL-1 using the small molecule inhibitor sabutoclax is effective in a variety of human melanoma molecular subtypes, including BRAFV600E and non-BRAF stage III/stage IV metastatic melanoma cell lines (Table 1). This evidence concerns the gene MCL1 and melanoma.